85 studies found for:    Alkermes
Show Display Options
Rank Status Study
1 Completed
Has Results
ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults
Condition: Alcoholism
Interventions: Drug: Medisorb naltrexone 380 mg;   Drug: Medisorb naltrexone 190 mg
2 Recruiting A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
Condition: Schizophrenia
Intervention: Drug: Aripiprazole Lauroxil
3 Completed
Has Results
ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)
Condition: Alcohol Dependence
Interventions: Drug: Medisorb naltrexone 190 mg;   Drug: Medisorb naltrexone 380 mg
4 Recruiting A Phase 1 Safety Study in Adults With Schizophrenia
Condition: Schizophrenia
Intervention: Drug: ALKS 3831
5 Recruiting A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
Condition: Schizophrenia
Interventions: Drug: ALKS 3831;   Drug: Olanzapine
6 Recruiting A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
Condition: Schizophrenia,
Interventions: Drug: ALK3831;   Drug: Olanzapine;   Drug: Placebo
7 Recruiting A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
Condition: Major Depressive Disorder
Interventions: Drug: ALKS 5461;   Drug: Placebo
8 Active, not recruiting A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
Conditions: Schizophrenia;   Alcohol Use Disorder
Interventions: Drug: Samidorphan + olanzapine (ALKS 3831);   Drug: Placebo
9 Completed A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
Condition: Major Depressive Disorder
Interventions: Drug: ALKS 5461;   Drug: Placebo
10 Completed A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study
Condition: Major Depressive Disorder
Interventions: Drug: High Dose ALKS 5461;   Drug: Low Dose ALKS 5461;   Drug: Placebo
11 Completed A Study of ALKS 3831 in Adults With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Samidorphan (Low Dose);   Drug: Samidorphan (Medium Dose);   Drug: Samidorphan (High Dose);   Drug: Placebo;   Drug: Olanzapine
12 Completed
Has Results
A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: ALKS 9072;   Drug: Placebo
13 Completed An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
Condition: Schizophrenia
Intervention: Drug: Aripiprazole Lauroxil
14 Recruiting A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
Condition: Schizophrenia
Intervention: Drug: ALKS 3831
15 Completed A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
Condition: Major Depressive Disorder
Intervention: Drug: ALKS 5461
16 Completed A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
Conditions: Schizophrenia;   Schizoaffective Disorder
Intervention: Drug: Aripiprazole Lauroxil
17 Completed Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
Condition: Renal Impairment
Intervention: Drug: ALKS 5461
18 Completed A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers
Condition: Healthy
Interventions: Drug: Moxifloxacin;   Drug: ALKS 5461;   Drug: Placebo
19 Enrolling by invitation A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
Condition: Schizophrenia
Intervention: Drug: ALKS 3831
20 Completed A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers
Condition: Healthy Volunteers
Intervention: Drug: ALKS 5461

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years